Latest Conference Articles

Sabizabulin Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Nivolumab/Rucaparib Combo Induces Clinically Effective Outcomes in mCRPC Subgroup

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.

Ribociclib/Letrozole Combo Yields Significant OS Benefit in Postmenopausal HR+/HER2- Advanced Breast Cancer

The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.

ctDNA a Viable Surrogate for OS in Previously Treated Metastatic Uveal Melanoma

Circulating tumor DNA was a better predictor for survival than RECIST 1.1 for patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma assigned to tebentafusp.

Datopotamab Deruxtecan May Lead to Antitumor Activity in Advanced NSCLC With Genomic Alterations

The antibody drug conjugate datopotamab deruxtecan demonstrated safe antitumor activity in patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations.

Optical Genome Mapping Offers Potential Tool to Assess Genomic Complexity in CLL

Optical genome mapping was found to effectively detect most abnormalities defined by standard methods, such as chromosome banding analysis, chromosomal microarrays, and fluorescence in situ hybridization, as well as several additional abnormalities of unknown clinical significance, in patients with chronic lymphocytic leukemia.

Trastuzumab Duocarmazine Shows PFS Benefit in Pretreated, HER2+ Metastatic Breast Cancer

Vic-trastuzumab duocarmazine yielded an improved progression-free survival over standard physician’s choice chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer.

Atezolizumab Plus Cabozantinib Shows Meaningful Clinical Activity in mCRPC, Including High-Risk Subsets

The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.

Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2+ Breast Cancer

Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.

cfDNA-Based MRD Assessment Is Feasible, Yields Highly Concordant Results in Relapsed/Refractory CLL

The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.

Pembrolizumab/Chemo With or Without Bevacizumab May Represent New Frontline SOC in Cervical Cancer

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates in patients with persistent, recurrent, or metastatic cervical cancer.

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

Adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma.

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

Pembrolizumab/Olaparib Combo Shows Promising Antitumor Activity in mCRPC

The combination of pembrolizumab plus olaparib produced promising antitumor activity in men with molecularly unselected docetaxel-pretreated metastatic castration-resistant prostate cancer.

Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC

Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial.

Relatlimab/Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma

The addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.

Osimertinib/Bevacizumab Combo Does Not Improve PFS in EGFR-Mutant NSCLC

The combination of osimertinib and bevacizumab did not produce a superior progression-free survival benefit vs osimertinib alone in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation.

Trastuzumab Deruxtecan Impresses With Clinical Activity in HER2-Mutant NSCLC

Fam-trastuzumab deruxtecan-nxki showcased robust and durable antitumor activity in previously treated patients with HER2-mutant non–small cell lung cancer.

CRISPR/Cas9 and mRNA-Based Technology Allows for Gene Editing and Expression in CLL Cells

CRISPR/Cas9 and mRNA-based gene editing and expression was found to be feasible in evaluating primary chronic lymphocytic leukemia cells.

Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

COVID-19 Continues to Result in High Admission, Fatality Rates Among Patients With CLL

COVID-19 continued to result in high admission and fatality rates among patients with chronic lymphocytic leukemia during the first 13 months of the pandemic, and although risk of severe infection was determined to be independent of age, CLL status, and treatment, being age 75 years or older was revealed to be a significant risk factor for death.

Cabozantinib Demonstrates Real-World OS Benefit in Second-Line RCC

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Perioperative Cabozantinib Yields Promising Results in mRCC

Perioperative treatment with cabozantinib induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma

Novel Immunotherapy Options Prompt Paradigm Shift in NSCLC Treatment

A shift in the NSCLC treatment paradigm came in the form of immunotherapy, which has since seen significant progress—mostly in the past decade.

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Trastuzumab Deruxtecan Elicits Encouraging Activity in Western Patients With HER2+ Gastric/GEJ Cancer

Splicing Molecule Delays Leukemic Infiltration in CLL, Has Targeted Therapy Potential

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Nivolumab/Ipilimumab Demonstrates Superior Likelihood of Long-Term Survival Vs Sunitinib in Advanced RCC

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.